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Detrimental  effects of maternal  smoking  on  the  term  placental  proteome  and  steroid-metabolizing  activi-
ties, and maternal  hormone  levels,  were  studied  by  using  seven  non-smoker  and  seven  smoker  placentae.
Smoking  signiﬁcantly  affected  18%  of  protein  spots.  The  functional  networks  affected  were i) cell  mor-
phology,  cellular  assembly  and  organization,  cellular  compromise  (15 hits)  and ii)  DNA  replication,
recombination,  and  repair,  energy  production,  nucleic  acid metabolism  (6 hits).  Smoking  signiﬁcantly
up-regulated  such  proteins  as, SERPINA1,  EFHD1  and  KRT8;  and  down-regulated  SERPINB2,  FGA  andoetus
aternal smoking
etabolism
lacenta
roteomics
teroid hormones
HBB.  Although  maternal  plasma  steroids  were  not  signiﬁcantly  altered,  the  catalytic  activity  of  CYP1A1
was  increased  whereas  CYP19A1  activity  was reduced  by  smoking.  Furthermore,  transcript  expression
of  CYP1A1  and  CYP4B1  were  induced  while  HSD17B2,  NFKB  and  TGFB1  were repressed  by  smoking.  The
observed  smoking  induced  wide-spread  changes  on  placental  proteome  and  transcript  levels  may  con-
tribute  to the  lowered  birth  weights  of  the new-born  child  and  placenta.
© 2016  The  Authors.  Published  by  Elsevier  Inc.  This  is an  open  access  article  under  the CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).. Introduction
Tobacco smoke contains over >7000 [1] harmful substances that
an have direct effects on placental and foetal cell proliferation
nd differentiation. Many of these substances, such as polycyclic
romatic hydrocarbons, readily pass through the placental barrier
nto the foetal compartment [2]. Maternal smoking increases the
isk of miscarriage, ectopic pregnancy, placenta praevia and foetal
rofacial clefts in early pregnancy and foetal growth restriction,
lacental insufﬁciency, placental abruption, premature rupture of
lacental membranes and preterm delivery in late pregnancy [3,4].
ong-term, prenatal exposure to smoking is a major risk factor for
espiratory ailments in children [5], and it may  impair their innate
nd adaptive immunity [6]. In addition, the risks for childhood and
dulthood obesity [7], cardiovascular disease [8] and impaired fer-
ility [9] in the offspring are increased by maternal smoking.
∗ Corresponding author at: School of Pharmacy, Faculty of Health Sciences, Uni-
ersity of Eastern Finland, P.O. Box 1627, FIN-70211 Kuopio, Finland.
E-mail address: markku.pasanen@uef.ﬁ (M.  Pasanen).
ttp://dx.doi.org/10.1016/j.reprotox.2016.05.009
890-6238/© 2016 The Authors. Published by Elsevier Inc. This is an open access article uXenobiotic-induced oxidative stress, including maternal smok-
ing, results in placental-associated syndromes and structural
changes in placenta, such as increased villous mesenchymal col-
lagen content, trophoblastic membrane thickening, decreased
vascularization, villous arteriole oedema and basal plate calciﬁ-
cation [3]. Such alterations can result in impaired trophoblast
proliferation, differentiation and regulation, as well as disturbed
mRNA transcript levels and altered activities of xenobiotic and
steroid metabolizing enzymes [10,11]. This highlights the need for a
systematic analysis of placental proteins altered by maternal smok-
ing. In addition, since the term placenta is one of the few tissues that
can be used to assess the developmental environment of the new-
born child, it would be of considerable value if markers of placental
xenotoxicant exposure could be identiﬁed.
In this proof of concept study, we  selected a 2-D gel approach to
enable us to also examine isoform changes, which have functional
implications, as well as expression changes in placental proteins
following smoke-exposure, as previously published for the human
foetal liver [12].
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Proteomic analysis of the human placenta at term. (A) Representative 2-D SDS PAGE showing signiﬁcantly altered protein spots following signiﬁcant smoke-exposure
(p  < 0.05, ≥1.2-fold change). The spot numbers in red denote the spots shown in (C) and (D). Cleaved SERPINA1 (1-D Western blot of individual placental samples, n = 7/group),
but  not intact protein or transcript, was signiﬁcantly increased in smoke-exposed placentae (B). 2-D Western blot (using the same protein pools as used for the proteomic
analysis) (C) conﬁrmed that SERPINA1 was present in multiple protein spots. VIM was  signiﬁcantly increased according to proteomic analysis but 2-D Western blot (D)
demonstrated that the blue highlighted spots did not overlap with the primary antigen and total immuno-recognised VIM was decreased in smoke-exposed placentae, as
shown by 1-D Western blot of individual placental samples (E). (F) Cluster analysis of the signiﬁcantly altered 2-D protein spot volumes demonstrates separation of the
non-smoker and smoke-exposed groups. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
24 P. Huuskonen et al. / Reproductive Toxicology 63 (2016) 22–31
Table 1
Demographic and perinatal data of the non-smoking and smoking groups.
Variable Non-smokersa Smokersa p-Valueb
Maternal age (years) 32.14 ± 6.28 26.00 ± 3.74 0.026*
Number of previous pregnancies 2.43 ± 0.53 2.14 ± 1.07 0.456
Duration of pregnancy (weeks) 39.65 ± 0.66 39.21 ± 1.60 1.000
Birth  weight (g) 3719.29 ± 196.86 3202.50 ± 309.38 0.002**
Placental weight (g) 680.83 ± 63.12 588.57 ± 73.35 0.165
a Non-smokers = 4 male, 3 female; Smokers = 7 males.
b As determined by Mann-Whitney U test, Values are shown as mean ± SD. Non-smokers vs. smokers.
* p < 0.05.
** p < 0.01.
Table 2
Comparison of the biochemical data between the non-smoking and smoking groups.
Variable Non-smokers (n = 7) Smokers (n = 7) p-valuea
Blood cotinine (ng/ml) <2.00b 51.51 ± 26.94(16.78–96.84) –
EROD  (pmol*mg/min) 0.30 ± 0.34 (0.02–0.78) 151.28 ± 180.56 (1.77–516.28) 0.001**
ECOD (pmol*mg/min) 5.50 ± 4.14 (1.93–13.86) 297.38 ± 264.79 (13.02–782.60) 0.001**
AROM (pmol*mg/min) 33.01 ± 7.28 (22.05–45.28) 27.78 ± 31.36 (10.84–98.26) 0.026*
GST (nmol*mg/min) 178.89 ± 36.45 (126.19–219.25) 230.41 ± 85.89 (183.98–418.27) 0.209
UGT  (pmol*mg/min) 5.00 ± 1.38 (3.66–7.28) 5.37 ± 1.89 (3.65–8.69) 0.902
Values are shown as mean ± SD and range in brackets below.
EROD = 7-ethoxyresoruﬁn O-deethylase, ECOD = 7-ethoxycoumarin O-deethylase, AROM = aromatase, GST = glutathione S-transferase, UGT = uridine 5′-diphospho-
glucuronosyltransferase.
a As determined by Mann-Whitney U test.
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. Materials and methods
.1. Human placental tissue
Fourteen full-term human placentae were obtained, with
pproval of the local ethic committee, from Kuopio University Hos-
ital, Finland and conducted according to the principles of the
eclaration of Helsinki. Maternal smoking was conﬁrmed with a
uestionnaire during pregnancy and conﬁrmed by measurement of
aternal cotinine levels using a liquid chromatography and mass
pectrometry (LC–MS) method with a lower sensitivity of 2 ng/ml
13]. Activities associated with the diagnostic placental enzymes
-ethoxycoumarin O-deethylase (ECOD) and 7-ethoxyresoruﬁn
-deethylase (EROD) were determined as a measure of smoking-
nduced cytochrome P450 subfamily 1A1 (CYP1A1) activity. All
lacentae, except for three non-smoker placentae, were obtained
rom vaginal deliveries and were collected immediately after deliv-
ry. After delivery, connective tissue and coagulated blood were
emoved from the placenta and placental tissue was  rinsed in cold
aline solution. Small pieces (5–10 g) including the central area of
he placenta were excised, frozen in liquid nitrogen and stored at
80 ◦C. For 2-D gel proteomics, equal amounts of protein from each
ndividual placenta were pooled according to maternal smoking
tatus and then four replicate gels were electrophoresed for each
roups separately. For 1-D gels and Western blot, all 14 samples
ere electrophoresed individually in separate lanes.
.2. Measurement of placental enzyme activity
EROD activity was measured to determine the induction of
YP1A1 according to Burke et al. [14]. The activity of ECOD was
easured as a general marker for placental CYP-associated activ-
ties using the method of Greenlee and Poland [15]. Aromatase
AROM) activity was measured to determine CYP19A1 steroid-
etabolizing activity by the method of Pasanen [16]. Microsomal
DP-glucuronosyltransferase (UGT) activity was measured using
he ﬂuorescent microplate method [17] while glutathione S-transferase (GST) activity was measured by the method of Habig
et al. [18].
2.3. Quantiﬁcation of serum steroid hormones
Ten maternal steroid hormones (oestrone, testosterone,
androstenedione, androstanedione, dehydroepiandrosterone,
dihydrotestosterone, progesterone, pregnenolone, 17-OH-
progesterone and 17-OH-pregnenolone) were quantiﬁed in
whole blood samples collected at delivery using a validated liquid
chromatography and tandem mass spectrometry (LC–MS/MS)
method [19].
2.4. Extraction of total RNA
Total RNA was  extracted with a GenElute Kit (Sigma-Aldrich,
MO,  USA) or with a Qiagen AllPrep mini kit (Qiagen Ltd., Crawley,
UK) followed by DNase treatment (Ambion Turbo DNA-Free Kit,
Ambion/Life Technologies, USA). The quantity of RNA was analysed
with a NanoVue (GE Healthcare, USA) spectrophotometer and the
integrity was  monitored by gel electrophoresis. The total RNA was
stored at −80 ◦C.
2.5. Extraction of protein
Proteins were extracted from placentae with a Qiagen AllPrep
DNA/RNA/Protein mini kit (Qiagen Ltd., Crawley, UK), see Ref. [20].
Tissues were homogenized following the manufacturer’s instruc-
tions with two main modiﬁcations: (i) the addition of protease
inhibitors (Protease Inhibitor Cocktail, Sigma-Aldrich Company
Ltd., Gillingham, UK) to the lysis buffer (RLT) to maximize protein
integrity and yield and (ii) the re-suspension of protein pellets in
Modiﬁed Reswell Solution [21]. Reproducibility of protein recovery
and quality is shown in Supplementary Fig. 1.
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Table  3
Relative ACTB-normalized expressions of transcripts of interest in the term human
placenta. Bold text denotes transcripts where maternal smoking had a statistically
signiﬁcant effect on transcript expression.
Gene Non-smokers Smokers p-valuea
Xenosensors
AHR 1 ± 0.29 1.98 ± 0.42 0.701
Endocrine receptors
KISSR 1 ± 0.44 0.89 ± 0.42 1.000
Steroidogenic enzymes
AKR1C3 1 ± 0.49 1.44 ± 0.81 0.523
CYP11A1 1 ± 0.49 0.49 ± 0.45 0.702
CYP19A1 1 ± 0.54 0.66 ± 0.71 0.259
HSD3B1 1 ± 0.50 0.90 ± 0.60 0.710
HSD3B2 1 ± 0.43 1.13 ± 0.47 0.898
HSD11B2 1 ± 0.37 0.54 ± 0.65 0.097
HSD17B1 1 ± 0.66 0.29 ± 0.38 0.702
HSD17B2 1 ± 0.32 0.15 ± 0.37 0.048
HSD17B6 1 ± 0.77 1.44 ± 0.81 0.705
POR  1 ± 0.47 0.43 ± 0.60 0.710
Phase I enzymes
CYP1A1 1 ± 0.64 142.86 ± 0.95 0.001
CYP2B6 1 ± 0.76 0.26 ± 0.58 0.898
CYP4B1 1 ± 0.63 6.88 ± 1.45 0.026
CBR1 1 ± 0.48 0.83 ± 0.54 0.535
EPHX1 1 ± 0.54 3.37 ± 0.49 0.201
Phase II enzymes
GSTA1 1 ± 0.59 1.69 ± 0.67 0.701
GSTP1 1 ± 0.28 3.21 ± 0.48 0.159
GSTT1 1 ± 0.54 0.60 ± 0.53 0.798
NQO1 1 ± 0.95 5.73 ± 0.71 0.201
Other pathways
GGT1 1 ± 0.96 0.01 ± 0.32 0.203
SERPINA1 1 ± 0.52 2.59 ± 0.46 0.250
TGFB1 1 ± 0.28 0.28 ± 0.40 0.046
FOS  1 ± 0.40 0.58 ± 0.25 0.999
NFKB 1 ± 0.42 0.22 ± 0.27 0.047
WISP2 1 ± 0.33 1.10 ± 0.35 0.818
CEBPB 1 ± 0.50 0.36 ± 0.34 0.798
IGF1 1 ± 0.70 0.10 ± 0.56 0.250
IGF2  1 ± 0.30 1.17 ± 0.25 0.688
Values are transformed to relative expression ± SEM. Percentual expressions were
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a As determined by ANOVA.
.6. Quantitative real-time PCR
cDNA was synthesized with the First-Strand cDNA synthesis
echnique (M-MuLV Reverse Transcriptase, Fermentas/Thermo Sci-
ntiﬁc, USA) and 2 g of total RNA was used in each synthesis.
eal-time PCR was performed using Taqman primer probe sets
Applied Biosystems/Life Technologies, USA) or SYBR (Brilliant II,
gilent technologies). Gene expression was normalized with -
ctin (ACTB) and each sample were measured in triplicate. The
ommercial probes and primers used are presented in Supplemen-
ary Table 1.
.7. Proteomics
For small-scale or proof of concept studies where proteomics
s used, we have found that pooling samples to build-in biologi-
al variation, with quadruplicate gel electrophoresis to contribute
he technical variation is a successful design. Therefore, protein
ools, to which individual placentae contributed equally in term of
rotein quantity, were prepared for each experimental group and
oluble proteins separated by 2-DE in quadruplicate using commer-
ial 7 cm gels, as previously described [21]. The gels were stained
ith Colloidal Coomassie Brilliant Blue, scanned and analysed
ith Progenesis SameSpots software, V6.01 (Nonlinear Dynamics,Toxicology 63 (2016) 22–31 25
Newcastle, UK). The software was  used to combine the gel quadru-
plicates and to calculate fold-changes and signiﬁcance. Brieﬂy, a
single reference gel for the whole experiment was selected from
one of the four control gels (Fig. 1A), based on image quality,
this also served as the reference gel for the control group while
the highest quality gel in the smoking group served as the ref-
erence gel for that group. Spots around the edge of the gel were
excluded and spots were detected based on all detected spots
in all 8 gels followed by automatic alignment, ﬁrst to reference
gels for each group separately and then to the experiment ref-
erence gel. The alignments were checked manually and poorly
matched spots within groups were excluded from the analysis.
Additional manual editing was  not required. Spots on all gels
were normalised (no gels were excluded from the analysis) using
the automatic normalisation routine of the software (see http://
totallab.com/samespots-technical-details/for further information).
Spots with fold-differences of ≥1.2-fold at p < 0.05 were included
in the overall analysis. Differentially-expressed protein spots were
selected for spot cutting once statistical signiﬁcance (provided
within SameSpots by ANOVA of log-normalised spot volumes) had
been independently veriﬁed by the authors (see Statistical Analysis
below) and all were consistently expressed across all 8 gels with
fold-differences of ≥1.5-fold at p < 0.05. Molecular masses and pI
values of spots of interest were estimated from separate gels elec-
trophoresed with pH and MW markers. Proteins in the gel pieces
were digested with trypsin and analysed see Ref. [21] for details.
Mass lists in the form of Mascot Generic Files were created auto-
matically and used as the input for Mascot MS/MS  Ions searches
of the NCBInr database using the Matrix Science web  server
(www.matrixscience.com). The default search parameters used
were: Enzyme = Trypsin, Max. Missed cleavages = 1; Fixed modiﬁ-
cations = Carbamidomethyl (C); Variable modiﬁcations = Oxidation
(M); Peptide tolerance ± 1.5 Da; MS/MS  tolerance ± 0.5 Da; Peptide
charge = 2+ and 3+; Instrument = ESI-TRAP. Statistically signiﬁcant
MOWSE  scores and good sequence coverage were considered to be
positive identiﬁcations.
2.8. 1-D gel electrophoresis and 1-D and 2-D western blot
Individual (n = 7/group) placental protein extracts were elec-
trophoresed (30 g protein/lane) on 26-lane 1-DE 4–12% Bis-Tris
gels (Invitrogen Ltd, Paisley, UK) under reducing conditions (MOPS
buffer, Invitrogen) [20,21]. The same pooled placental protein sam-
ples as used for proteomics (section 2.7 above) were also used
to generate additional 2-D gels. Both 1-D and 2-D gels were
transferred to ImmobilonTM-FL membranes (Millipore (UK) Ltd,
Watford, UK) as described previously [20,21]. Odyssey Two-Colour
Protein Molecular Weight Markers (LI-COR Biosciences UK Ltd,
Cambridge, UK) were electrophoresed in 3 lanes of every gel. The
membranes were blocked (1 h, room temperature) with (Odyssey
Blocking Buffer, 927–4000: LICOR +PBS) and were incubated with
primary antibodies (diluted in blocking buffer + PBST) at 4 ◦C
overnight: (i) Transgelin (TAGLN2) 0.001 g/ml, goat, AHP2034,
ABD Serotec, Kidlington, Oxfordshire, UK; (ii) Carbonic anhydrase-1
(CA1) 1:1000, mouse, H00000759-A01, Abnova, Stratech Scien-
tiﬁc Ltd, Newmarket, Suffolk, UK; (iii) Peroxiredoxin-1 (PRDX1)
1:500, rabbit, PA0007, LabFrontier, no longer available; (iv) Alpha-
1-antitrypsin (SERPINA1) 1:500, rabbit, HPA00129, Sigma-Aldrich
Company Ltd, Gillingham, Dorset, UK. Membranes were also
immuno-stained with an anti-ACTB (anti -actin) load control from
a different species (1:5000, mouse, ab8226, Abcam Plc, Cambridge,
Cambridgeshire, UK or 1:10000, rabbit A5060, Sigma-Aldrich).
IRDye® infrared secondary antibodies were supplied by LI-COR.
Protein bands were visualized using the LI-COR Odyssey® Infrared
Imaging System and the resulting electronic images were analysed
using TotalLab TL120 software (v2008.1; Nonlinear Dynamics Ltd,
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ewcastle-upon-Tyne, UK) to determine the molecular weights
nd band volumes. The band volumes of ACTB were compared
etween groups to check the validity of this load control for pla-
entae from the non-smoking and smoking groups. 1-D load control
DS PAGE gel of all placental protein extracts studied is presented
n Supplementary Fig. 1.
.9. Statistical and pathway analysis
Statistical signiﬁcance of demographic, biochemical and hor-
onal data was carried out by Mann-Whitney U-test and data are
resented as mean ± SD, and P-values <0.05 were considered sta-
istically signiﬁcant. The normality of proteomic data distribution
as tested with the Shapiro-Wilk test and where distribution of
ata was skewed, they were log-transformed prior to analysis or
nalysed using the non-parametric Wilcoxon test. The 1-DE West-
rn blot band volumes (normalized relative to ACTB expression
eparate for each lane) and normalized spot volumes (% of total
pot volume for each gel separately) were compared in control and
moke-exposed groups, using one-way ANOVA. Statistically sig-
iﬁcant differences in log-transformed, normalized volumes were
n important determinant of the spots selected for identiﬁca-
ion by LC/MS-MS. Unless otherwise stated, data are presented as
ean ± SEM. Where fold-changes are presented, a positive value
ndicates an increase, and a negative value is a reduction, relative
o controls. Proteins and transcripts exhibiting treatment-speciﬁc
lterations in expression were analysed using Ingenuity Pathway
nalysis (IPA, Ingenuity Systems, http://www.ingenuity.com), as
escribed previously [12,21,22].
. Results
.1. The weights of newborns were reduced by maternal smoking
The mean birth weight of neonates was signiﬁcantly (p < 0.01)
educed in the smoking group compared with those in the non-
moking group (Table 1). In the smoking group, a non-signiﬁcant
rend (p = 0.165) for reduced placental weight was observed.
omen  were signiﬁcantly younger (p < 0.05) in the smoking group
ompared to the non-smoking group (Table 1).
.2. Maternal smoking alters placental metabolizing enzyme
ctivity
In the smoking group, placental enzyme activities ECOD and
ROD were signiﬁcantly induced (p < 0.01) and AROM levels sig-
iﬁcantly repressed (p < 0.05) compared to the non-smoking group
Table 2). However, GST and UGT were not altered. A signiﬁ-
ant increase was observed in placental mRNA transcript levels of
YP1A1 and CYP4B1 (Table 3) in the smoking group (p < 0.01 and
 < 0.05, respectively).
.3. Smoking has little effect on maternal plasma steroid
ormone levels
Maternal plasma steroid hormone concentrations demon-
trated a wide inter-individual variation without any signiﬁcant
lterations between the smoking and non-smoking groups
Table 4). In the smoking group one mother displayed, low estro-
en and progestogen levels, and exceptionally high androgen levels
lthough her placental AROM activity was similar to the others.
f the 10 steroidogenic enzyme transcripts quantiﬁed (Table 3),
nly hydroxysteroid dehydrogenase 17B2 (HSD17B2) displayed a
igniﬁcantly decreased expression in the smoking group (p < 0.05).Toxicology 63 (2016) 22–31
3.4. The placental proteome is disturbed by maternal smoking
Maternal smoking signiﬁcantly affected 72 protein spots
(p < 0.05, ≥1.2-fold change) out of 392 protein spots included in the
study (based on quality criteria of size and reproducibility). Mater-
nal smoking increased 27 and decreased 45 protein spot volumes
(Fig. 1A). Sixteen of the most altered and consistent of these pro-
tein spots were identiﬁed by using LC–MS/MS (Table 5). Because
protein spots can contain more than one protein and different pro-
tein isoforms may  have different migration patterns [22], selected
proteins with likely roles in the placenta were further analysed by
Western blot. Maternal smoking signiﬁcantly increased the cleaved
(48 kDA) form of -1-antitrypsin (SERPINA1) but not the 55 kDa
full-length protein or transcript (Fig. 1B, C). Vimentin (VIM) was
identiﬁed in two  protein spots, which had signiﬁcantly increased
spot volumes in the smoking group (Table 5 and Fig. 1D). In the
2-D Western blot of VIM the antibody used marginally overlapped
with the spots in blue in Fig. 1D. Therefore, VIM is a minor com-
ponent of spot # 2047 and 2048 (Fig. 1D, peptide intensity ration
2.30:1.00 in favour of SERPINA1) and, in contrast, immunodetected
VIM protein was signiﬁcantly decreased (Fig. 1E). A non-signiﬁcant
trend for decreasing immune-detectable protein expression of car-
bonic anhydrase 1 (CA1), peroxiredoxin 1 (PRDX1) and transgelin
2 (TAGLN2) was observed among smokers (Fig. 2), similar to the
proteomics ﬁndings (Table 5). By using Ingenuity Pathway Analy-
sis (IPA), the proteomic ﬁndings shown in Table 5 were mapped to
two networks: I) Cell Morphology, Cellular Assembly and Organi-
zation, Cellular Compromise (Fig. 3, Supplementary Table 2) and II)
DNA Replication, Recombination, and Repair, Energy Production,
Nucleic Acid Metabolism (Fig. 4, Supplementary Table 2). These
pathways mapped to toxicological and biological functions shown
in Supplementary Table 3 and included liver function and disease
and cell death, survival and function. Canonical pathways in the
term human placental proteome affected by maternal smoking
(Supplementary Fig. 2) include several detoxiﬁcation and metabolic
pathways as well as signalling and blood function pathways. Based
on the pathway analysis, eight mRNA transcripts associated with
placental consequences of smoking, intra-uterine growth restric-
tion, or with SERPINA1, were quantiﬁed by qPCR. Among the
transcripts measured (Table 3 “other pathways”), only nuclear fac-
tor kappa-light-chain-enhancer of activated beta cells (NFKB) and
transforming growth factor, beta 1 (TGFB1) were statistically sig-
niﬁcantly decreased.
4. Discussion
In this study, placental proteins relating to two main func-
tional protein networks (i: Cell Morphology, Cellular Assembly and
Organization, Cellular Compromise; ii: DNA Replication, Recombi-
nation, and Repair, Energy Production, Nucleic Acid Metabolism)
were signiﬁcantly affected by maternal smoking in the human
term placentae. The protein affected included constructs of
haemoglobin subunits and protective proteases (e.g. SERPINA1)
and proteins directly involved in cellular structure or carbon diox-
ide metabolism.
SERPINA1 is a protease inhibitor that belongs to the serine pro-
teinase (serpin) superfamily and protects against inﬂammatory
cells initiated cell damage [24]. In addition, there are multiple forms
of SERPINA1, which are associated with the expression of the dif-
ferent pro-inﬂammatory molecules [25]. In the present study, the
expression of the cleaved 48 kDa form of SERPINA1 (NP 000286)
protein was  signiﬁcantly lower in the smoking group compared
to non-smoking group (fold-change −1.5). However, maternal
smoking signiﬁcantly increased (fold-change +1.6 to +1.8) expres-
sion levels of three other SERPINA1 protein variants (1QMB A,
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Table  4
Maternal hormone concentrations for the non-smoking and smoking groups.
Hormone Non-smokers (n = 7) Smokers (n = 7) p-valuea
Estrone 119.98 ± 56.90 (44.36–216.10) 135.44 ± 88.45 (21.96–248.41) 0.710
Testosterone 0.23 ± 0.13 (0.076–0.385) 0.65 ± 1.07 (0.082–3.042) 0.535
Androstenedione 3.18 ± 0.59 (2.23–3.87) 4.76 ± 4.92 (1.16–15.68) 0.805
Androstanedione <1.33b <1.33b –
Dehydroepiandrosterone 8.16 ± 3.13 (5.15–13.40) 12.66 ± 5.63 (5.15–21.28) 0.165
Dihydrotestosterone <0.325b <0.325b –
Progesterone 3189.35 ± 1795.52 (1036.93–5740.57) 3005.66 ± 1179.88 (493.65–4305.20) 1.000
Pregnenolone 97.49 ± 27.46 (50.66–127.96) 109.74 ± 45.92 (17.99–167.78) 0.535
17-Hydroxyprogesterone 81.66 ± 56.06 (35.83–184.28) 79.74 ± 45.13 (29.61–164.53) 1.000
17-Hydroxypregnenolone 12.19 ± 4.44 (5.24–19.45) 18.62 ± 10.73 (5.45–32.00) 0.209
Values are shown as mean ± SD and range in brackets below. All units of variables are nM.
a As determined by Mann-Whitney U test.
b Below limit of quantitation.
Table 5
Identiﬁcation of proteins in 16 2-D gel spots signiﬁcantly affected by maternal smoking in human term placenta. The proteins are grouped into two networks according to
the  Ingenuity Pathway Analysis (IPA) (see Supplementary Table 2).
Spot # Gene symbol Protein name Accession # Fold-change p-valuea MW pI MOWSE  Score
Network 1: Cell Morphology, Cellular Assembly and Organization, Cellular Compromise
118 SERPINB2 Plasminogen activator inhibitor 2 NP 002566 −1.9 0.041 46.8 5.46 528
1828  SERPINA1 Alpha-1-antitrypsin NP 000286 −1.5 0.035 46.9 5.37 974
2047b SERPINA1 Alpha-1-antitrypsin (or S variant) 1QMB A +1.8 0.004 36.6 5.44 1086
1077  SERPINA1 Alpha-1-antitrypsin AAH15642 +1.8 <0.001 39.1 5.27 942
2048b SERPINA1 Alpha-1-antitrypsin AAB59495 +1.6 0.016 46.8 5.43 716
1468b PPIB Peptidyl-prolyl cis-trans isomerase B AAA52150 −1.5 0.008 22.8 9.33 309
1487b PRDX1 Peroxiredoxin 1 NP 002565 −1.5 0.036 22.3 8.27 480
1468b FGA Fibrinogen alpha chain 0501249A −1.5 0.008 26.6 9.08 444
1470  FGA Fibrinogen alpha chain 0501249A −1.7 0.002 26.6 9.08 425
2047b VIM Vimentin AAA61279 +1.8 0.004 53.7 5.03 426
2048b VIM Vimentin AAA61279 +1.6 0.016 53.7 5.03 724
1793  COL1A1 Collagen alpha 1(I) Chain AAH36531 −1.5 0.005 139.9 5.70 187
2105d COL1A1 Collagen alpha 1(I) Chain AAH36531 −1.6 <0.001 140.0 5.70 125
1966  KRT8 KRT8 protein AAH11373 +1.5 0.017 41.1 4.94 582
1107  KRT18 KRT18 protein, cytoskeletal CAA31377 −1.5 <0.001 47.3 5.27 1337
Network 2: DNA Replication, Recombination, and Repair, Energy Production, Nucleic Acid Metabolism
1342  PNP Purine nucleoside phosphorylase NP 000261 −1.6 <0.001 32.3 6.45 684
1379  CA1 Carbonic anhydrase 1 NP 001729 −1.5 0.004 28.9 6.59 617
1468b ATP5F1 ATP synthase subunit b, mitochondoral AAH05960 −1.5 0.008 28.9 9.45 218
1487b TAGLN2 Transgelin-2 NP 003555 −1.5 0.036 22.5 8.41 450
1969c HBB Hemoglobin subunit beta 2DXM D −2.6 0.032 15.9 6.55 643
1349  EFHD1 EF-hand domain-containing protein D1 NP 079479 +1.6 0.004 27.0 5.34 408
a As determined using log-normalized spot volumes.
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[b More than one protein highly likely to be in the spot.
c Poor gel match with MW and pI but sequence coverage of 94% and an ion score
d Poor sequence coverage and gel MW match.
AH15642 and AAB59495). This suggests that maternal smoking
an disturb transcript splicing in placenta. According to the liter-
ture there are contradictory data based on placental SERPINA1
rotein expression levels. This is due to the differences in risk fac-
ors for pregnancy: SERPINA1 was increased in placentas of obese
others [26] and decreased in preeclamptic mothers [27]. SER-
INA1 is increased in the lung and sputum of smokers [28], which,
ogether with our data and known effects of smoking on the pla-
enta [29], suggests that speciﬁc SERPINA1 isoforms could serve as
 biomarker for oxidative stress. It is also possible that the alter-
tions in placental SERPINA1 expression levels reﬂect responses
o external stress factors and, therefore, could reﬂect the overall
aturation process or well-being of the foeto-placental unit. Strik-
ngly, our data showed good agreement with a recently published
tudy on the effects of growth restriction on the human placenta in
hich SERPINA1 was increased and SERPINB2 decreased [30]. The
dentiﬁcation of multiple proteins in other spots (e.g. #1468) and
heir isoforms (e.g. VIM) will require follow-up in further studies
ecause of the potential functional importance of these differences
23].suggests an accurate identiﬁcation.
Other placental proteins affected by maternal smoking included
carbonic anhydrase 1 (CA1), haemoglobin subunit  (HBB) and
plasminogen activator inhibitor 2 (SERPINB2). The expression of
SERPINB2 protein was signiﬁcantly decreased in the placentae of
smokers. Biologically SERPINB2 is a coagulation factor produced in
the human placenta. It inactivates urokinase plasminogen activa-
tor (uPA) and tissue plasminogen activator (tPA) [31]. In line with
our data, SERPINB2 transcript was  signiﬁcantly down-regulated in
a study performed with umbilical cords of maternal smokers [32].
Potentially, the down-regulation of SERPINB2 will lead to increased
risk for haemorrhage during pregnancy. As a consequence, this
may  increase risk for gestational complications such as placental
abruption in smokers.
HBB expression was  reduced signiﬁcantly in the placentae
from smoking women. Lower levels of proteins associated with
haemoglobin synthesis could lead to inadequate oxygen transfer
to the foetus and increase risk of intrauterine oxygen depletion
and foetal growth retardation seen in maternal smoking. Similarly,
placentae from severe preeclamptic mothers have demonstrated
comparable decrease in haemoglobin–-chain levels [27]. In con-
trast, HBB, HBA and HBG levels were signiﬁcantly elevated in
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big. 2. 1-D Western blot of individual placental samples (n = 7/group) showed a sim
his  was  not statistically signiﬁcant.
roteomic studies of: (i) cord blood from maternal smokers [33]
nd (ii) the effects of growth restriction on the human placenta
30]. Carbonic anhydrases are key components in transporting
arbon dioxide from tissues to circulation, and maintaining the
cid-base balance in tissues. Therefore, the signiﬁcant reduction
n placental levels of CA1 combined with the repressed synthesis
f haemoglobin subunits in the smoking group would be expected
o exert synergistic effects leading to impaired oxygen supply and
cid-base imbalance.
Levels of transcripts identiﬁed by IPA analysis of the smoking-
esponsive placental proteome, speciﬁcally those encoding NFKB
nd TGFB1,  were signiﬁcantly decreased in the placenta by mater-
al smoking. Oxidative stress is usually associated with increased
FKB, which also mediates responses to hypoxia and up-regulates
ellular responses to inﬂammation in placental cells [34]. Failure
f NFKB levels to increase in placentae from maternal smokers
ay  limit the ability of the placenta to protect itself from the out-
omes rising from the oxidative stress [35]. However, this will
equire further study due to the occurrence of at least two NFKB
soforms. TGFB1 is a multifunctional cytokine that regulates placen-
al trophoblast cell proliferation and differentiation, and hormone
roduction [36]. A decrease in transcript levels has, therefore, the
otential to affect several aspects of placental function and growth
nd to increase the risk of placental insufﬁciency.
Maternal smoking also affected several intra-cellular structure-
elated members of the placental proteome. Signiﬁcant decreases in
he levels of collagen (COL1A1), ﬁbrinogen (FBA), keratin (KRT18),
nd VIM (the latter measured by Western blot) occurred if the
other smoked. The expression changes in these speciﬁc placental
tructural proteins may  reﬂect growth restriction, structural and
unctional consequences, e.g. placental abruption, insufﬁciency,
remature rupture of placental membranes and preterm delivery
3]. VIM is a component of the cytoskeleton, which is required to
aintain cellular integrity and its expression levels were altered
n women suffering preterm labour [37]. However, in the cur-
ent study no difference was seen in terms of pregnancy duration
etween smoking and non-smoking mothers.end as found in the proteomic ﬁndings for (A) TAGLN2, (B) CA1 and (C) PRDX1, but
Maternal smoking altered several functional enzyme activities
in the placental samples (Table 3). The placental monooxygenase
activities, EROD and ECOD, were both induced among smokers’
placentae probably by constituents of the cigarette smoke [10].
CYP19A1 activity was also decreased in the smokers’ placentae [38],
which could lead to reduced placental oestrogen synthesis capac-
ity and housekeeping functions. Maternal smoking also led to an
induction of CYP1A1 and CYP4B1 mRNA levels and a repression
of CYP19A1 mRNA levels. These ﬁndings agree with our previous
study [10], although gross CYP1A1 and CYP19A1 protein levels
were not signiﬁcantly altered in our Western blot analysis (data
not shown). Among the hydroxysteroid dehydrogenases, the mRNA
of HSD17B2 was  repressed in the smoker group. HSD17B2 con-
verts testosterone to androstenedione, estradiol to estrone, and
20-alpha-dihydroprogesterone to progesterone. In human placenta
HSD17B2 is located in the endothelial cells lining the foetal com-
partment. It has been hypothesized that HSD17B2 acts as a barrier
to reduce the rate of estradiol secretion into the foetal circu-
lation [39] and it is possible, therefore, that maternal smoking
alters circulating foetal estradiol levels. This is supported by our
recent publication demonstrating signiﬁcantly increased second
trimester estrogen levels in human foetal plasma [40]. The maternal
serum steroid hormone levels displayed wide inter-individual vari-
ations in both of the studied groups. Despite the changes observed
in the placental hormone metabolism no signiﬁcant alterations
were detected in maternal serum steroid hormone levels, although
cigarette smoking has been demonstrated to affect maternal steroid
hormone levels and reduce estriol levels in the cord blood [41].
All pregnancies included in the present study were classiﬁed as
clinically “normal” and resulted in healthy babies and none of the
women underwent long-term medication during gestation. When
the smoking and non-smoking groups were analysed, foetal sex
was added as a covariate and there were no signiﬁcant interactions
between foetal sex and maternal smoking for any of the reported
data. Sample size in this study was  small but was  sufﬁcient to
conﬁrm the epidemiological ﬁndings that maternal smoking was
associated with lower birth weights [4]. One limitation of the study
is that the women  were signiﬁcantly younger in the smoking group
P. Huuskonen et al. / Reproductive Toxicology 63 (2016) 22–31 29
Fig. 3. Network 1 (Cell Morphology, Cellular Assembly and Organization, Cellular Compromise) identiﬁed from maternal smoking effects on the proteome of the term human
placenta. Networks were generated through the use of Ingenuity Pathway analysis. The intensity of color represents degree of up-regulation (purple) and down-regulation
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dred).  A key to the identity of the node shapes is included in the ﬁgure. Dashed and
ndicate binding while closed arrows indicate action of ﬁrst on second node and o
eferences to colour in this ﬁgure legend, the reader is referred to the web version o
ompared to non-smoking group. In general, smoking mothers are
ounger than non-smokers as demonstrated in the USA where 20%
f pregnant women aged <25 years smoke and 9% of those aged >35
ears [42]. Our data agrees with the previous ﬁndings that the mean
lacental weight was reduced in the smoker group [43]. However,
lso maternal age may  inﬂuence placental weight or morphometry
44]. The changes observed in the present proteomic analysis will
ot directly reﬂect to the weight or size or histology of placenta
s reported in other studies [45]. Nonetheless our data support the
orking hypothesis that maternal smoking affects multiple funda-
ental cellular systems controlling the growth, development and
unction of placenta. This is emphasized in Supplementary Table
 where the biological functions with the largest number of mem-
ers with overlapping proteins identiﬁed in the present study were
ound in the categories of cell growth, survival, movement and
eath. One caveat of course is that by looking at the term pla- lines represent indirect and direct interactions respectively. Lines without arrows
rrows indicate translocation from ﬁrst to second node. (For interpretation of the
 article.)
centa we  cannot determine when over the 9 months of pregnancy,
the changes in placental function occurred. This does not reduce
the importance of studying the term placenta both due to its own
intrinsic biomedical importance and because it is a readily accessi-
ble product of conception that can act as a cumulative read-out for
the whole of gestation.
5. Conclusions
In conclusion, based on the literature, altogether 4239 proteins
have been identiﬁed in human placental tissue, covering around
21% of the human proteome [46]. In the present study we show
that maternal smoking signiﬁcantly affected term placental levels
of at least 70 proteins. The two  functional protein networks affected
were: (1) cell morphology, cellular assembly and organization;
(2) DNA replication, recombination, and repair, energy production,
30 P. Huuskonen et al. / Reproductive Toxicology 63 (2016) 22–31
Fig. 4. Network 2 (DNA Replication, Recombination, and Repair, Energy Production, Nucleic Acid Metabolism) identiﬁed from maternal smoking effects on the proteome
of  the term human placenta. Networks were generated through the use of Ingenuity Pathway analysis. The intensity of color represents degree of up-regulation (purple)
and  down-regulation (red). A key to the identity of the node shapes is included in the ﬁgure. Dashed and solid lines represent indirect and direct interactions respectively.
Lines  without arrows indicate binding while closed arrows indicate action of ﬁrst on second node and open arrows indicate translocation from ﬁrst to second node. (For
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fnterpretation of the references to colour in this ﬁgure legend, the reader is referred
ucleic acid metabolism. The clinical signiﬁcance of increased SER-
INA1 expression among smokers’ placentae is not known but its
nown functions suggest signiﬁcant deviation in placental func-
ion in cigarette smoking women. The changes described at the
lacental proteome and transcript levels may  reﬂect the increased
xidative stress due to maternal smoking, resulting in lowered birth
eight of a new born child and placenta. Based on the concept,
evelopmental origin of diseases, it remains unresolved whether
he maternal smoking-induced placental proteomic changes reﬂect
o the wellbeing or morbidity of children later in life.
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